PSCH News and Press, PowerShares S&P SmallCap Health Care Portfolio From 03/13/24

2024-03-13 10:10:00 ET Summary Jeff Hirsch, editor-in-chief of The Stock Trader’s Almanac, and Carter Worth, CEO and founder of Worth Charting, discuss their outlook for 2024 with MoneyShow's Mike Larson. Jeff expects a strong year for stocks, with gains of 8-15% broadly sp...

2024-03-13 04:10:26 ET Summary PTH tracks the DWA Healthcare Technical Leaders Index, selecting U.S. Health Care stocks based on a proprietary relative strength measure. There are about 300 U.S. Health Care stocks in the selection universe. The Index only requires 30, and any poin...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-02-23 04:05:00 ET Summary Within healthcare, an area that has been negatively impacted the last couple of years is the pharmaceutical manufacturing value chain. Several capital goods and materials sectors experienced recessionary conditions last year, which caused weak fundam...

2024-02-07 01:53:00 ET Summary A sub-$3trn 2023 for M&A, but new year pipeline gives hope. Rising follow-on equity in 2023 signals latent appetite. Unstoppable debt capital markets hit $8.9trn for FY2023. By Lucille Jones, Senior Manager, Deals Intelligence and...

2024-01-31 04:36:00 ET Summary 2023 was characterized by narrow leadership and multiple expansions. While last year’s gains have led to headline valuations appearing stretched, there are many segments of the market that are not as aggressively priced. With the expectati...

2024-01-16 04:50:00 ET Summary Why US banks could be poised for a rebound? Sectors primed for a pivot if the Fed cuts. The outlook for healthcare and real estate. The potential for interest rate cuts this year by the U.S. Federal Reserve is raising the outlook for ...

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...